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Hemodialysis access failure: A call to action. Recent evidence
suggests that the cost as well as the morbidity associated with the
maintenance of hemodialysis access is increasing rapidly; cur-
rently, the cost exceeds 1 billion dollars and access related
hospitalization accounts for 25% of all hospital admissions in the
U.S.A. This increase in cost and morbidity has been associated
with several epidemiological trends that may contribute to access
failure. These include late patient referral to nephrologists and
surgeons, late planning of vascular access as well as a shift from
A-V fistulaes to PTFE grafts and temporary catheters, which have
a higher failure rate. The reasons for this shift in the types of
access is multifactorial and is not explained by changes in the
co-morbidities of patients presenting to dialysis. Surgical prefer-
ence and training also appear to play an important role in the
large regional variation and patency rate of these PTFE grafts.
We propose a program for early placement of A-V fistulae, a
continuous quality improvement, multidisciplinary program to
monitor access outcome, the development of new biomaterials,
and a research plan to investigate pharmacological intervention to
reduce development of stenosis and clinical interventions to treat
those that do develop, prior to thrombosis.
While intermittent hemodialysis for the treatment of
patients with acute renal failure was introduced by Kolff in
1943, the development of chronic hemodialysis therapy for
end-stage renal disease was not feasible until the introduc-
tion of the external arteriovenous shunt by Quinton and
colleagues in 1960. In an era characterized by rapid tech-
nical development, Brescia and colleagues developed the
endogenous arteriovenous fistula in 1966 [1], and pros-
thetic subcutaneous interpositional “bridge” grafts were
developed shortly thereafter [2]. Since these pioneering
days, the pace of technical improvements in permanent
hemodialysis vascular access has slowed to a crawl (Table
1). While there have been minor refinements in the bioma-
terials and contours of prosthetic bridge grafts, no major
advances in permanent hemodialysis access have been
made over the past three decades.
During this time, the rapid growth of end-stage renal
failure programs in the United States and worldwide has
been accompanied by a tremendous increase in hemodial-
ysis vascular access-associated morbidity. In its latest re-
port, the USRDS estimates that in 1995, the cost of access
morbidity was approximately $7,871 per patient per year at
risk, and the annual global cost to Medicare represents 14
to 17% of total spending for hemodialysis patients per year
at risk [3]. This access-related morbidity, and its attendant
costs, may be accelerating. For example, Feldman et al
reported that access related morbidity accounted for ap-
proximately 15% of hospital stays prior to 1989; however,
the most recent evidence suggests that access-related mor-
bidity accounts for at least 25% of all hospital stays, and in
the first year of dialysis may constitute up to 50% of all
patient care costs [3–5]. These data become even more
relevant to nephrology practice in the face of a major
interest by Medicare and some Health Maintenance Orga-
nization (HMO) to capitate medical care to end-stage renal
disease (ESRD) patients.
In addition to this enormous financial burden, for pa-
tients, dialysis staff, nephrologists and surgeons, the fre-
quency and unpredictability with which hemodialysis vas-
cular access thrombosis develops is an enormous
frustration. Vascular access-related morbidity also contrib-
utes significantly to a reduction in the delivered dose of
dialysis (a major factor in the relative risk of mortality of
chronic dialysis patients) through the use of temporary
catheters or reduced blood flow. Additionally, this access
related morbidity leads to a significant reduction in the
quality of life of dialysis patients. Finally, in our opinion,
vascular access “grief” (as it is referred to in our institu-
tions) has been responsible for turning off more graduates
of internal medicine residency programs from a potential
career in nephrology than any other aspect of nephrology,
at a time when several reports point to an impending
shortage of nephrologists.
MAGNITUDE OF THE PROBLEM
Epidemologic data analyzed by the USRDS from HCFA
data and other sources clearly demonstrate that lack of
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appropriate timing of vascular access placement substan-
tially contributes to subsequent access failure.
In 1993, approximately half of the patients starting
ESRD therapy in the U.S. have had no permanent access
placed or attempted before initiation of dialysis therapy for
ESRD, and 27% have a temporary catheter 30 days after
initiation of therapy. In fact, only 25% of patients have had
a permanent access placed 30 days before initiation of
dialysis therapy [6].
These percentages need to be examined in the context of
substantial data that early placement of the access, partic-
ularly A-V fistulae, generally correlates with improved
outcome of the access [6]. In addition, Collins et al have
recently shown that not only access outcome, but patient
outcome strongly correlates with the timing of access
placement [7]. The relative risk of mortality in patients who
had accesses placed six months or more before initiation of
therapy was one half the mortality risk of patients who have
had accesses placed less than one month before ESRD
therapy. Whether these glaring differences in patient out-
comes relates to the more frequent use of temporary
catheters (with its attendant risk of infection, sepsis and
underdialysis) has not been explored [8–10].
A number of patients do indeed present in advanced
stages of uremia with minimal or no prior medical care, and
need to be initiated on hemodialysis therapy with tempo-
rary catheters; however, it is unlikely that such patients
account for the 50% of all patients starting dialysis therapy
without a permanent access. One must presume that a
certain percentage are patients who have been followed by
primary care physicians (“gatekeepers”), internists or other
medical subspecialties and referred to nephrologists’ care
late in the course of their illness. A substantial number of
these patients were probably followed by nephrologists who
have not adequately planned their access for initiation of
dialysis [6].
In an analysis by Woods and colleagues, 70% of incident
hemodialysis patients knew their renal function was abnor-
mal but only 58% had seen a nephrologist four months
before ESRD therapy [11]. Patients who have had nephrol-
ogy contact more than four months prior to ESRD therapy
were significantly more likely to have a permanent access at
the time of initiation, more likely to have an A-V fistulae
(versus a PTFE graft) and more likely to have been told to
avoid venipuncture in one arm. On the other hand, 14% of
patients had seen a nephrologist only three months before
ESRD therapy and 25% had seen a nephrologist one
month or less before initiation of hemodialysis. These data
suggest that there is a high prevalence of delayed nephrol-
ogy referral on a national level.
A related problem is that in 1996, 19% of patients were
using a cuffed permanent catheter (compared to 10% in
1993) at 60 days after start of hemodialysis [6]. Further-
more, despite well documented concerns about develop-
ment of subclavian stenosis with its attendant chronic
problems, the subclavian vein was used as the access site in
an alarming 21.6% of incident patients in 1993, and 9% in
1996 [3, 6].
TYPES OF VASCULAR ACCESS
Arteriovenous fistulae and polytetrafluoroethylene graft
The predominant types of permanent vascular access in
use for chronic hemodialysis currently are the primary
arteriovenous (A-V) fistulae and the polytetrafluoroethyl-
ene (PTFE) A-V graft. The results of most, but not all,
previous studies have suggested an improved survival of
primary A-V fistulae compared to PTFE grafts. A recent
study by the USRDS, analyzing data from a cohort of 784
patients starting dialysis in 1990, has shown that the relative
risk of access failure for a patient with an A-V fistula
compared with a patient with a PTFE graft was 67% lower
risk at the age of 40 years, 54% lower at the age of 50 years
and 24% lower risk at the age of 65 years [12]. These data
are supported by the only previous large multicenter pro-
spective cohort study of first permanent vascular access
survival among incident patients, the Canadian Hemodial-
ysis Morbidity study. This study demonstrated a 71% lower
risk for failure of an A-V fistula compared to PTFE graft,
after adjustment for the effect of age, gender, and co-
morbid conditions [13]. Although one retrospective study
has shown that if primary failures of A-V fistulaes are
included in the analysis, the survival of the A-V fistulae and
PTFE may be comparable [14], what is clear is that the
number of procedures and revisions to maintain graft
patency are twice as high in PTFE grafts as in developed
A-V fistulaes [6].
Despite these studies, the prevalence of PTFE graft use
in the U.S. has steadily increased from 51% in 1986 to 65%
in 1990 of all ESRD patients starting dialysis with perma-
nent accesses [15]. In 1993, the last year for which data are
currently available, the percentage of permanent hemodi-
alysis accesses made of PTFE had increased to 73% of
incident patients [3]. However, there were substantial re-
gional variations, ranging from only 23% of incident pa-
tients with PTFE grafts in the New England region, to 85%
in the Southeastern states [15]. The magnitude of these
regional variations in PTFE use is not likely to be due solely
to differences in prevalence of co-morbid conditions or
their severity, but may reflect differences in patient referral
pattern and surgical practice patterns (see below).
Table 1. Breakthroughs in hemodialysis vascular access
Permanent
External arteriovenous shunt 1960
Endogenous arteriovenous fistula 1966
Prosthetic bridge grafts 1973
From 1973 to 1997 ??
Temporary
Central vein catheters 1980
Cuffed central vein catheters 1990
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Similarly, Hirth and colleagues have found that neither
the increase in the prevalence of co-morbidities of patients
presenting to dialysis nor the widespread use of high flux
dialyzers (which ostensibly require higher blood flows) can
account for the declining use of fistulaes relative to grafts
[15]. The wide regional variation in the types of vascular
access also suggests that other factors aside from increased
co-morbidity account for this shift in types of vascular
accesses. Finally, it must be noted that in Europe the
percentage of patients with endogenous arterio-venous
fistulas exceeds 70 to 80% and in Japan is reported to reach
90%.
ROLE OF VASCULAR SURGEONS
A common “conversation piece” among most nephrolo-
gists is the frustration they face in feeling at the mercy of
the vascular surgeon(s) in their institution with regard to
the timeliness, interest, quality control and follow-up data
of hemodialysis access procedures. Despite its financial
rewards, the formation of new vascular accesses appears to
be of little interest, and is often performed by surgical
residents with minimal support or supervision by the at-
tending surgeons. Similarly, the urgency of treatment of
access thrombosis that is felt by the patient and nephrolo-
gist is often not shared by the surgeon. Thrombectomies of
the vascular access and the surgical treatment of the
attendant venous stenosis is often delayed, necessitating
the placement of temporary catheters with their attendant
short-term (discomfort to the patient, bleeding, pneumo or
hemothorax) and long-term (infection, sepsis, subclavian
stenosis and inadequate dialysis) complications.
In the only published study that examined this issue, the
results of a multivariate analysis showed that the outcome
of the vascular access was more dependent on the specific
surgeon than on any other parameter studied. Three-year
patency rates varied from 34% to 62% depending on the
surgeon [16]. In a more recent study, Feldman and col-
leagues have shown that the patency of new vascular access
grafts was associated with the level of training of the
surgeons performing the procedure. Not having an attend-
ing surgeon present at the time of graft placement was
associated with a 2.4-fold increase in relative risk of access
failure from any cause. This finding was consistent when
examining non-infective and infective failures separately,
and highlights the importance of having surgeons with a
high degree of training and experience perform vascular
surgery [17]. These variations in the standard of surgical
practice may be one of the factors that explain regional
variations, not only in the preference for PTFE grafts but
also in the rates of PTFE access failures, which ranges from
45% below the reference to 33% above the reference
region in the U.S. [18].
Surgeons’ attitude toward the types of vascular access has
also been suggested as a potential explanation for the rapid
shift from A-V fistulas to PTFE grafts. In their analysis of
the USRDS data, Held and colleagues found that in 1991
the 10% of the surgeons who created the most fistulae
accounted for 72.0% of all fistulae, while the 10% who
created the most grafts accounted for 44% of all grafts.
Based on this, Held et al suggest that “the distribution of
surgeons proficient in performing different vascular access
techniques, differences and changes in the subspecialties of
the surgeons performing access procedures and the training
received in surgical residency and fellowship program, and
the rate of reimbursement for different types of access
procedures relative to the effort and difficulty involved may
influence the use of fistulas and grafts” [15].
ROLE OF NEPHROLOGISTS
In the face of these data, there has been a lack of active
efforts to find appropriate solutions by the nephrology
community. This practical abandonment of the decision
making process in the formation and treatment of vascular
access complications by nephrologists has been mirrored by
a paucity of clinical and biochemical research on the causes
and preventive measures of vascular access stenosis. To our
knowledge, despite the enormous cost of vascular access
care, there has not been a National Institutes of Health
(NIH) sponsored effort to develop a “consensus confer-
ence” or an organized “Request For Proposal” on the
subject of vascular access in dialysis patients, although one
may be in the planning stages currently at the NIH. Until
recently, the priorities assigned to the USRDS special
studies did not place this topic high enough to warrant a
focused review.
LESSONS LEARNED IN VASCULAR ACCESS
Nevertheless, the magnitude of the problem of hemodi-
alysis vascular access has not gone unnoticed and individual
research over the past decade by Schwab et al [19–21],
Besarab et al [22–25], Beathard [26–28], Sands et al
[29–31], Sherman et al [32–34] and others [35–37] has led
to a greatly improved understanding of the pathophysiology
and appropriate treatment for vascular access morbidity.
From these and other investigators, we have learned a
number of lessons about hemodialysis vascular access (Ta-
ble 2). These generalizations include the understanding of
the process of central vein stenosis, its devastating conse-
quence and the role that temporary subclavian catheters
have played in this process [38–40]. Another learned lesson
is that, once mature, autologous fistulae maintain better
patency and require less salvage procedures than prosthetic
grafts; however, the failure rate of autologous fistulaes in
the first year after formation is high and these failures are
often related to lack of time for “maturation” of these
fistulae [14]. Other lessons include the need to monitor
access function prospectively in order to detect incipient
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access malfunction [21, 32, 41, 42], and once diagnosed, the
need to improve the natural history of such grafts by
angioplasty and/or surgical intervention [43–45].
Despite these hard-won achievements, progress to date
in maintaining and improving hemodialysis vascular access
primary and secondary patency has been incremental at
best. While it varies from center to center, cumulative graft
patency for prosthetic grafts over a two year period is
approximately 30%, even with a large number of salvage
procedures. In addition to the costs of salvage procedures,
the costs associated with routine vascular access monitoring
for stenosis and for diagnosis and treatment of established
venous stenosis in PTFE grafts are difficult to ascertain, but
undoubtedly are escalating enormously in an effort to
maintain access patency.
PREDICTIVE TESTS OF ACCESS FAILURES
Research over the past decade has led to a better
understanding of processes or measures that may be help-
ful in predicting the severity of vascular access venous
stenosis. In an elegant conceptual breakthrough Schwab et
al proposed monitoring the venous pressure at a set blood
flow rate of 200 ml/min during the dialysis procedure as a
non-invasive method for detecting the formation of stenosis
at the venous anastomosis, a harbinger of access thrombo-
sis [19]. Refinements to the method of measurement of
these intra-access “venous” pressures have been proposed
by Besarab and Van Stone [24, 25, 35]. However, the
physiologic principle upon which such measurement has
been advocated (that is, distal “venous” stenosis results in
elevation of hemodynamic pressures proximal to the steno-
sis) may not apply to a large number of accesses for reasons
listed in Table 3. In a recent angiographic study the
presence of critical high-grade stenosis at the venous
anastomosis was found in 38 out of 84 (45%) of grafts,
while a critical stenosis was found in the central vein in 34%
of grafts, 15% had a mid-graft stenosis and 4% had stenosis
at the arterial anastomosis, with many grafts having multi-
ple stenoses [46]. The stenosis at sites other than the
venous anastomosis attenuates the usefulness of “venous”
pressure monitoring as a predictive measure of access
failures [47].
Several additional methods for the detection of incipient
prosthetic graft failures have been advocated, ranging from
the measurement of venous pressures under static (zero
dialyzer flow) conditions [24], measurements of access
recirculation [28, 33], acute decrements of dialysis dose or
“negative” arterial pressures that develops as the pump
speed exceeds the blood flow that can be obtained from the
access. The limitations of studies of “venous” pressures as
well as arterial pressures have already been alluded to
(Table 3). Furthermore, while “venous” pressures, or mea-
sures of recirculation or negative arterial pressures may be
useful, they are often late manifestations of this problem.
Recent studies have also demonstrated that recirculation
only occurs when access blood flow is lower than prescribed
dialysis blood flow. Since this occurs very late in the life of
an access, tests of recirculation have been deemed not
useful in the detection of early access stenosis [48].
Recent evidence suggests that detection of low access
blood flow rates is an early, sensitive and specific predictor
of both venous stenosis and subsequent thrombosis [49, 50].
Table 2. What lessons have we learned in the past three decades?
1. Subclavian catheters beget subclavian vein stenosis, with resultant
long-term morbidity.
2. Temporary catheters are associated with short-term and long-term
morbidity and are best avoided.
3. Native fistula, if initially successful, function longer and better than
prosthetic bridge grafts.
4. Most PTFE grafts fail after development of venous stenosis from
myointinal hyperplasia.
5. Screening tests can predict those patients with venous stenosis who
are at higher risk for thrombosis.
6. Prophylactic angioplasty when venous stenosis is identified likely can
prolong access survival but is costly, and comparative long-term
patency has not been established.
Table 3. Limitations of current access monitoring techniques
I.“First generation” access monitoring tests
“Venous pressure”
1. Presence of other intra-access stenoses (mid-graft, arterial or
“central” vein)
2. Placement of dialysis needle, needle size, blood flow at time of
measurement and pressure attenuation along bloodline
3. Low systemic hemodynamic pressure
4. Insensitivity of pressure measurement device of dialysis
machines
5. Cannulation may bypass stenosis or obstruction
6. May detect stenosis, but is only a moderate predictor of access
thrombosis
Recirculation
1. Develops only when blood pump flow demand exceeds access
blood flow
2. Poor predictor of impending access failure
3. Late manifestation of venous outlet stenosis
Acute drop in dose of dialysis
1. Non-specific (can result from a number of other complications)
2. Decreases primarily when recirculation is high (See B)
II. Second generation access monitoring sites
Access blood flow
1. Applies mostly to PTFE grafts; often ineffective in fistulae,
especially radial fistulae due to their multiple and collateral
run-offs
2. The lower the blood flow velocity, the higher the risk of
thrombosis; blood flows of # 800 ml/min have a higher rate of
thrombosis than blood flows $ 1,000 ml/min in PTFE grafts.
For A-V fistulae, there is increased risk of thrombosis as access
blood flow drops lower than approximately 400 ml/min.
3. Decrements of blood flow (. 25% decrease) are associated with
a much higher relative risk of thrombosis in fistulae and grafts
4. Can predict impending access thrombosis in the short term
Doppler Ultrasound
1. Provides accurate anatomical pathology
2. Provides a good estimate of blood flow velocity
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This concept appears to be gaining increased acceptance
[41]. A major advantage of intra-access blood flow mea-
surement is that, in contrast to “venous pressures,” flow is
affected by stenoses irrespective of their localization. Mea-
surement of intra-access blood flow has been technologi-
cally difficult until recently, but is now readily available by
Doppler ultrasound measurements [51–53], magnetic res-
onance angiography, or with a technologically more user-
friendly and less expensive device, based on the Fick
principle, the so-called “ultrasound dilution technique”
developed by Krivitski [36]. Krivitski has recently validated
this new approach, whereby measurement of recirculation
with the blood lines reversed, can accurately measure
access blood flow in a practical, convenient and reproduc-
ible way.
In a recent study in a large ESRD population, several
parameters were simultaneously measured to define their
value in predicting the development of access thrombosis.
The results of this prospective study have confirmed that
intra-access blood flow determination, either by Doppler
ultrasound or the ultrasound dilution technique, is the most
predictive of these measures, and in prosthetic grafts, blood
flows of less than 800 ml/min is associated with stenosis of
greater than 50% in cross section and a progressively
higher risk of thrombosis in the ensuing three months [49].
A follow-up to that study suggests that sequential monitor-
ing of blood flow is potentially even more useful, since
decrements of intraccess blood flow by more than 25% was
associated with a relative risk of thrombosis of 10 times the
risk in accesses without a decrement in blood flow. A 50%
decrease in blood flow resulted in a 30-fold increase in
relative risk of thrombosis compared to those that do not
have a decrease in blood flow. It should be noted that while
the criteria of blood flow less than 800 ml/min applies to
grafts (and not native A-V fistulae), the predictive power of
a decrease in blood flow by more than 25% applies to both
grafts and fistulae [54]. Using the same physiologic princi-
ples, a recent study by Lindsay et al demonstrated that
measuring hemodialysis access flow rate by differentiated
conductivity also predicts access thrombosis [55].
If other studies support this concept, it is clear that the
measurement of blood flow in the access may need to
become a routine measurement in the dialysis unit. Once
these blood flows are below a “threshold” of 800 ml/min,
and particularly those accesses that have a rapid drop in
blood flow rates over time (for example, greater than 25%
decrease in blood flow over three months) may need to
have their anatomical structure studied. Ideally, the Dopp-
ler ultrasound should provide such a diagnosis, and may be
less costly and less invasive than an arteriogram [56].
Whether these studies are sufficient for surgical or radio-
logical intervention remains to be determined [29].
The high predictive value of a drop in intraccess blood
flow for thrombosis has two major implications: The first is
that the degree of venous stenosis is often progressive, and
a significant drop in blood flow (20 to 30%) carries higher
relative risk of thrombosis than a low flow in and by itself.
This is consistent with flow dynamics across a constriction
whereby flow is maintained (albeit at the risk of higher
pressures) until a critical stenosis is reached (usually .70%
stenosis), and afterwards flow is progressively reduced. The
second implication is that serial measurement of access
blood flow provides sufficient early warning of the “criti-
cality” of the stenosis so that early intervention may be
helpful [54].
While such research on predictors of incipient access
failure has been helpful (and to our knowledge, not sup-
ported by NIH), it can be argued that such research is
similar to the proverbial “closing the barn after the horse is
gone.” Except for one relatively old study, there has been
no prospective, randomized (double blind) study of ways in
which the development of the vascular access venous
stenosis may be retarded or abolished [57].
SALVAGE OF FAILING OR THROMBOSED ACCESS
While the availability of screening tests for incipient
access thrombosis with high sensitivity and specificity will
be helpful in diagnosing problems and providing an early
warning of access failure, the next step is to find out if these
“early warning signs” can be translated into an effective
method of correcting the problem and, most importantly,
whether such salvage procedures prolong access life. Sev-
eral retrospective or non-randomized studies suggest that
angioplasty or surgical revision of a stenotic lesion in-
creases the lifetime of a vascular access [14, 45, 55, 58–60].
However, a recent study of prophylactic balloon angio-
plasty (for .50% venous stenosis) versus observation alone
did not demonstrate benefit for angioplasty for either 6 or
12 month patency rates [61]. However, the lack of access
flow measurements before or after intervention, and im-
portant differences in patient (that is, access) characteris-
tics between the two groups of patients severely limits the
generalization of such findings. In the most recent study of
115 patients who developed thromboses in PTFE grafts,
assigned to surgical or radiological interventions, post-
operative graft function was found to be significantly better
in the surgical group [62]. However, the study did not
compare the success of repeat radiological interventions
(secondary patency) or the comparative costs of each of
these procedures. Studies of the effectiveness of prophy-
lactic interventions for treatment of low grade stenosis (50
to 75% of venous stenosis) before thrombosis occurs are
also needed, particularly with development of predictive
assessment tools based on sequential measurement of
access blood flow. Clearly, more studies and with a higher
number of patients are needed to address these important
issues.
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PROPOSED SOLUTIONS
Solving the problems of vascular access morbidity in the
21st century will require some of the ingenuity and re-
sourcefulness demonstrated by the generation of health
care providers in the 1960’s that paved the way for chronic
hemodialysis therapy to become a reality for so many
patients. A recent publication by the National Kidney
Foundation (DOQI) has outlined a series of clinical rec-
ommendations related to vascular access, and recom-
mended several important areas for improvement of access
outcome [63]. The following is our list of focus areas in the
hopes that true breakthroughs can occur in reducing he-
modialysis vascular access morbidity (Table 4). Because
these are recommendations that we need to focus on, each
will be discussed more extensively below.
Early placement of native A-V fistulae
Despite the almost universal acceptance of its long-term
superiority as a vascular access method, the frequency of
placement of A-V fistulae in the U.S. is small and declining
[64–68]. This has been attributed to the increased co-
morbidities of patients nearing end-stage renal disease,
although as discussed earlier, this may not be such an
overwhelming factor [15]. Nevertheless, there are other
factors more amenable to modification that we believe may
result in a higher percentage of native A-V fistulae in
incident patients.
Early start for access planning. In all patients who do not
have a living related transplantation available and planned,
we advocate the placement of an A-V fistula no later than
at a time the creatinine reaches 4 to 5 mg/dl or when
creatinine clearance is approximately 25 ml/min. While it is
difficult to predict rates of progression in individual pa-
tients, several studies have pointed out that progression
occurs faster in diabetic and proteinuric patients, who
constitute more than 50% of all patients starting ESRD
therapy and, therefore, earlier access placement may be
necessary in such patients.
This early placement not only allows time for fistulae to
develop, but even if it does not mature, it may dilate the
venous system sufficiently to improve the eventual success
of the PTFE graft. Importantly, having the A-V fistula
(with appropriate education and instruction) preserves that
arm from repeated venipuncture for blood drawing that
leads to sclerosis of the veins. Frequent monitoring of the
“maturity” of the fistulae, along with exercises (such as,
tourniquet placement) to develop the fistulae and ligation
of run-off veins if necessary should help in the development
of these accesses. The use of anti-platelet medications for
the first month after fistula formation may help prevent
early thrombosis, giving the access the chance to mature
(Table 5). It is reasonable, in our view, that a target of at
least 70% of patients with attempted and 50% developed
autologous A-V fistulae should be set as a goal for patients
presenting to dialysis by the year 2000. A microsurgical
technique of side to side anastomosis of the radial artery
and cephalic vein (with ligation of distal veins if necessary)
appears to be more successful in development of A-V
fistulae than end-to-side anastomosis, which is more com-
monly utilized (personal communication, S. O’Regan).
Upper arm brachio-cephalic fistulae as the initial access
have also been proposed to improve primary fistulae sur-
vival (personal communication, S. Schwab). These targets
are in accordance with the recently issued DOQI vascular
access clinical practice guidelines [63].
Part of this planning should include educating the patient
and heath care workers (nurses, physicians, etc.) about
“saving” the vasculature of patients with chronic renal
failure, particularly in the non-dominant arm. Placement of
the i.v. for “keep vein open” or placement of intra-arterial
lines to monitor blood pressure in intensive care units
should be restricted to true medical needs rather than a
reflex action or for convenience.
Early referral to the nephrologist. We believe that there are
sufficient data that early referral of patients with chronic
renal failure to nephrologists leads to reduced morbidity
(that is, hospitalization and costs) than if the patient is
managed by a primary care physician until uremia develops
[64, 69]. Although this concept has not been well presented
to managed care organizations, it may be time for organi-
zations such as the American Society of Nephrology,
National Kidney Foundation and Renal Physician Associ-
ation to actively become engaged in this process so vital to
patients with advanced renal disease.
Abolishing subclavian vein cannulation. The complica-
tions of these temporary HD catheters are devastating and
prohibit future placement of vascular accesses in the side of
cannulation Thus, placement of these HD catheters in the
subclavian vein should only be a last resort, and limited in
duration to a few days, particularly when other veins such
as the internal jugular or femoral veins are available
[38–40, 70].
Similarly, the cannulation of the subclavian vein for other
uses, such as Swan-Gantz catherization or i.v. access for
non-dialysis purposes should be discouraged for patients
with any degree of renal failure.
Peritoneal dialysis as bridge therapy. Except in emergent
situations where uremic symptoms or biochemical param-
eters (such as, hyperkalemia) need to be treated acutely
Table 4. What lessons haven’t we learned in the past three decades?
1. How to achieve early placement of native arteriovenous fistulas in
most chronic hemodialysis patients in the USA.
2. Effective pharmacological inhibition of myointinal hyperplasia.
3. Optimal screening techniques for venous stenosis.
4. Optimal multidisciplinary approaches to vascular access
management.
5. Development of better biomaterials and surgical techniques.
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with hemodialysis, nephrologists should consider the use of
peritoneal dialysis (PD) as temporary or “bridge” therapy
in patients who present with advanced stages of uremia but
who are otherwise not ideal candidates for long-term PD
therapy. The initiation of chronic therapy with PD, while
allowing an A-V fistulae (or PTFE graft) to mature, may
lead to improved long-term outcome of accesses and
patients [71].
Effective pharmacological inhibition of intimal
hyperplasia
It is clear that vascular access generally fails within the
first few weeks due to a thrombotic process, or thereafter
due to the development of intimal hyperplasia and venous
stenosis [72]. Despite the obvious importance of maintain-
ing primary access patency, there have been remarkably
few in vitro and ex vivo experiments and even fewer clinical
trials addressing the prevention of access stenosis and
thrombosis (Table 5).
Early studies clearly demonstrated that antiplatelet
agents are effective in preventing thrombosis of external
shunts and in preventing early native arteriovenous fistula
thrombosis. On the other hand, despite the extensive use of
PTFE grafts there is to date only one relatively large
prospective, randomized, placebo-controlled clinical trial
that examined pharmacologic approaches to decreasing the
rate of graft thrombosis [57]. The results of this study
demonstrated a significant decrease in the rate of throm-
bosis in patients with new PTFE grafts taking dipyridamole
(relative risk 0.35, P 5 0.02) and a trend toward a higher
rate of thrombosis in patients taking aspirin (relative risk
1.99, P 5 0.18). Differences between the groups became
manifest only after six months, probably reflecting differing
rates of intimal hyperplasia development at the venous
anastomosis, although this was not checked with Doppler
ultrasound or angiography. The results of this study were
surprising, since aspirin is generally considered to be a
more potent antiplatelet therapeutic agent than dipyridam-
ole.
Recent work by our laboratory may provide an improved
pathophysiologic understanding of the results of this clini-
cal trial [73, 74]. It is well known that the process of intimal
hyperplasia formation involves medial smooth muscle rep-
lication, migration to the intima, followed by further pro-
liferation and extracellular matrix deposition [75]. Ross has
formulated a “response to injury” hypothesis, in which a
prominent role is given to the effects of platelet-derived
growth factor (PDGF) and basic fibroblast growth factor
(bFGF) in stimulating both smooth muscle replication and
migration [76]. Using human aortic smooth muscle cells in
culture, we have recently demonstrated that dipyridamole
profoundly inhibits both PDGF- and bFGF-induced vascu-
lar smooth muscle cell proliferation. The effects of dipyrid-
amole on smooth muscle cell proliferation are reversible
over time and occur at concentrations comparable to
plasma concentrations obtained after oral administration of
conventional doses [74].
In a series of related experiments, we have demonstrated
that aspirin enhances PDGF-induced vascular smooth mus-
cle cell proliferation [74]. In smooth muscle cell cultures
activated with PDGF, aspirin results in an increase in
12-HETE production, an important intracellular messen-
ger and mitogen during smooth muscle cell activation, in
contrast to prostaglandin E2, the major cyclooxygenase-
derived product of arachidonic acid in smooth muscle cells
that is an inhibitor of activation and proliferation of these
cells [77]. Thus, aspirin may have a direct positive effect on
proliferation and mitogenesis of vascular smooth muscle
cell by inhibiting cyclooxygenase and stimulating lipoxygen-
ase pathways of arachidonic acid metabolism.
Further work is clearly needed to better define the
mechanisms by which dipyridamole and similar drugs may
affect intimal hyperplasia formation. Clinical trails are also
clearly needed to corroborate the findings of this one
relatively small trial. Nevertheless, the recommendation “to
Table 5. Pharmacological trials to prevent vascular access failure
Study Drug N patients Follow-up Results
Shunts
Kaegi, 1974 [99] Sulfinpyrazone 52 6 months 76% Thrombosis reduction
Harter, 1979 [100] Aspirin 44 5 months 56% Thrombosis reduction
Kobayashi, 1980 [101] Ticlodipine 107 3 months 21% Thrombosis reduction
A-V fistulas
Andrassy, 1974 [102] Aspirin 92 2 weeks 4% vs. 23% thrombosis
Grontoft, 1994 [103] Ticlodipine 42 1 month 11% vs. 47% thrombosis
PTFE grafts
Sreedhara, 1994 [57] Dipyridamole, aspirin 84 18 months Dipyridamole RR 0.35,
P 5 0.02
ASA RR 1.99
P 5 0.18
This analysis is limited to prospective randomized trials with $ 20 patients.
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take one baby aspirin a day” in an attempt to reduce PTFE
graft thrombosis is no longer an adequate recommenda-
tion, and may in fact be counterproductive. There are also
a number of novel potential pharmacologic approaches to
preventing intimal hyperplasia formation that have been
elegantly summarized by Sukhatme [78]. We join Dr.
Sukhatme in the plea that efforts in both basic science as
well as clinical trials aimed at reducing formation of intimal
hyperplasia associated with vascular access grafts be spon-
sored by the NIH.
Predictive tests of access failure and their costs
Based on the evidence discussed earlier, the measure-
ment of access blood flow is an early and sensitive test for
incipient access failure. This test can currently be per-
formed in the dialysis unit, either by the ultrasound dilution
technique or by Doppler ultrasound. The latter has the
additional advantage of localizing the site(s) and magni-
tude of the attendant stenosis. We propose that these tests
become an important adjunct to dialytic care.
The implementation of such a recommendation is ham-
pered by several regulatory issues related to the U.S. health
care system. HCFA denies reimbursement for tests and
procedures it considers “screening” or “preventive.” In
addition, the considerable lag between emerging technolo-
gies and their integration into a reimbursable CPT code has
made it economically difficult to acquire the necessary
equipment for ultrasound dilution (currently $10,000 in-
cluding a portable computer), when such tests are not
reimbursed. More recently, HCFA has even attempted to
disqualify reimbursement for Doppler ultrasound on the
grounds that these tests are part of access monitoring that
is integrated in the hemodialysis “composite” reimburse-
ment, and because the frequency of such tests has been
inconsistent in different regions of the U.S. Although
timely intervention by the Renal Physician Association and
the National Kidney Foundation has led HCFA to withhold
implementation of their blanket denial for reimbursement
of Doppler ultrasound, a more active dialogue is needed
between physicians and Medicare intermediaries to high-
light the medical and economic benefits of such tests and
other emerging technologies.
Subject to the limitations outlined in Table 3, the mea-
surement of venous pressures sequentially is a test that may
yield information on venous stenosis and is available at no
additional cost. In cases where the venous pressure is rising
and there are no other intra-access stenoses, this test may
be a sensitive and cost-effective, albeit late index of im-
pending access thrombosis.
Multidisciplinary approach to vascular access
management
Nephrologists need to be more proactive in the planning,
management and salvage of fistulas for hemodialysis access.
It is not clear why such a vital issue to the welfare of ESRD
patients has been delegated to having the dialysis nurse call
the secretary of the surgeon to arrange for a surgical
procedure. Direct communication at the planning stage is
vital and its practical implementation in a large academic
center has led to a steady improvement in the number of
autologous A-V fistulae and in frequency of thrombosis
[79]. Reliance on PTFE grafts as a first access is a “learned
practice” by many surgeons, and can only be changed by
persistent requests for placement of A-V fistulaes. More
importantly, short-term and long-term follow-up and doc-
umentation of such by each surgeon should be routine and
demanded by the nephrologist. Such documentation should
include a clear description of the anatomical relationship of
the graft, and as well as a description of the surgical
technique, sutures, etc., in addition to the usual demo-
graphic data. Equally important, and as an integral part of
a CQI team led by nephrologists and including surgeons
and radiologists, specific information to track access out-
come needs to be organized. Several parameters related to
access material, configuration, surgical technique, as well as
the attending surgeon needs to be organized in a database
[80–82]. In addition, any subsequent salvage procedure by
the radiologist or nephrologist needs to be documented in
a way that allows further analysis and plans for improve-
ment of outcome. Although these requests for quality
control information from radiologists and surgeons is not
likely to be welcomed by them, it is important to be
persistent in pursuing the information even at the risk of
changing referral patterns to surgeons who are willing to
participate in an effective quality improvement process. As
the cost of nephrological care is being capitated, it may also
be worthwhile to consider capitating the surgeons for
access care, and the radiologist for salvage procedures.
It must also be mentioned that there is anecdotal evi-
dence that peritoneal dialysis accesses placed by nephrol-
ogist appears to have a better outcome than surgically
placed catheters. Whether this information is evidence-
based or speculative, it is important that nephrologist
become more intensely involved in this area so vital to their
patients. Such involvement needs to start at the fellowship
training level by incorporating radiological intervention
techniques used in the care of accesses, as part of the
fellowship program. Examples of such an involvement is
clearly provided by cardiology fellows who train in ultra-
sound evaluation, angiography and angioplasty of coronary
stenotic lesions.
Finally, as part of this multidisciplinary approach, and as
an important element for improved outcome, an “access”
database should include the use of antiplatelet drugs and
low molecular weight heparin in a prospective, if not
randomized study. The lessons learned from such databases
can be a substrate for an effort by the NIH to organize a
multi-center basic science research to define approaches to
this vexing problem of neointimal hyperplasia and clinical
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research to define approaches to salvage procedures of
failed or failing PTFE accesses [83–85].
Development of better biomaterials
The ideal prosthetic materials for vascular access grafts
must possess a number of characteristics to be biocompat-
ible (Fig. 1). The luminal wall of the graft must be
thromboresistant, while the external wall should be rapidly
incorporated into surrounding tissues. The tendency to-
ward thromboresistance versus thrombogenicity of bioma-
terials used in vascular access grafts is largely determined
by the surface characteristics, types of proteins that selec-
tively and actively adsorb to the graft, and by the cells that
tend to adhere to the graft material [86].
While PTFE has been developed after experience with
other materials, there has been no other material that has
been proposed as an alternative. Since the introduction of
e-PTFE graft materials in 1973, there have been minimal
advances in developing biomaterials for vascular access;
even for PTFE, different weaving patterns and architec-
tural support may impact on outcome. Such studies are few
and far between.
There are also a number of biocompatibility disadvan-
tages to the use of e-PTFE biomaterials, which need to be
studied further [87]. Inflammation at the host-biomaterial
interface as a result of bioincompatibility may contribute to
the development of intimal hyperplasia in PTFE grafts. For
example, PTFE catheters used as venous access devices are
associated with a very high rate of development of throm-
bophlebitis during peripheral intravenous nutrition when
compared to biomaterials such as silicone [88, 89]. A
potential mechanism for this is that PTFE is strongly
hydrophobic, which may increase platelet activation [86, 90,
91]. Furthermore, macrophages adhere readily to PTFE
and become activated with the production of reactive
oxygen species and membrane-associated interleukin-1 and
tumor necrosis factor-a (TNF-a) [87, 92]. Finally, endothe-
lial cells adherent to PTFE bind human leukocytes more
readily than control endothelial cells [93].
A major biological problem with PTFE grafts is the
failure to achieve in vivo endothelialization throughout the
length of the graft [90]. This leads to repetitive episodes of
platelet deposition and inflammatory cell (platelet, neutro-
phils, macrophages) activation [94]. It has been suggested
that there may be better peri-graft tissue in-growth and
endothelialization using high porosity, non-reinforced
PTFE grafts (compared to the standard lower porosity
reinforced PTFE grafts in clinical use) and with the use of
vascular endothelial growth factor (VEGF) [14, 95, 96].
Recently, experimental approaches such as application of
shear stress to endothelial cells or retroviral transduction of
endothelial cells [97, 98] have been shown to increase
retention of endothelial cells on graft material in vitro.
Further research into methods to increase graft endotheli-
alization is clearly needed.
CONCLUSION
It has been said that “insanity is doing the same thing, in
the same way, and expecting a different result” (Roger
Milliken). As far as hemodialysis access, we can no longer
continue doing the same thing (very little indeed), the same
way (tabulating data on small scale studies), and expect that
the lives of our ESRD patients will be better or that the
costs of access care will diminish. It is time to change the
paradigm to work proactively and cooperatively to improve
the outcomes of hemodialysis access care. Beginnings are
half of the journey.
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